HM9: Patient engagement in the regulatory lifecycle of medicines

2D4A8424

The session was dedicated to considering how patient engagement is being considered as part of medicinal product development, approval, and post-approval phases. Involving patients in the regulatory decision-making process is advancing and progress has been made in evolving frameworks over the last few years. Four short presentations set the scene for discussion, with contributions from regulators, patient representatives and healthcare providers.

How to read this journal article 

Thank you for visiting Regulatory Rapporteur. Journal articles are restricted to registered users and TOPRA members.

Already a member or have an account? Sign in.

1. REGISTER FOR FREE

Free access to selected content

Register now to continue to access industry news, editorials and podcasts plus one member-only journal article each month.

  • Create your own library to save your favourite content.
Create a free account

2. Members login

Already a TOPRA member?

Log-in now using your MyTOPRA credentials, for unlimited access to all Regulatory Rapporteur journal articles, the online archive and latest industry news and podcasts.

Login

3. JOIN TOPRA

TOPRA membership

Become a TOPRA member and join our global regulatory affairs community.

  • Great savings on our events and training.
  • Be part of our dynamic international community.
  • Contribute to the profession.
  • Grow your skills and knowledge.
  • Take your career to the next level.

Become a member